Evidence map›Paper›PMID 40103461›Full record

ArticleCurrent pharmaceutical design2026

Synthesis and Characterization of Zn

Nasar Ahmed, Natasha Nazir, Muhammad Asif, M Adnan, M Fakhar-E-Alam, Muhammad Zubair, Khizar Ul Haq, Muhammad Aseer, Muhammad Atif, Safdar Ali

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nasar AhmedDepartment of Physics, King Abdullah Campus, The University of Azad Jammu and Kashmir, Muzaffarabad, 13100, Pakistan.
Natasha NazirDepartment of Physics, King Abdullah Campus, The University of Azad Jammu and Kashmir, Muzaffarabad, 13100, Pakistan.
Muhammad AsifDepartment of Physics, Government College University Faisalabad, Faisalabad, 38000, Pakistan.
M AdnanDepartment of Physics, Government College University Faisalabad, Faisalabad, 38000, Pakistan.
M Fakhar-E-AlamDepartment of Physics, Government College University Faisalabad, Faisalabad, 38000, Pakistan.
Muhammad ZubairDepartment of Bioinformatics and Biotechnology, Government College University Faisalabad, Faisalabad, 38000, Pakistan.
Khizar Ul HaqDepartment of Physics, Mirpur University of Science and Technology, New Mirpur City, Azad Kashmir, Pakistan.
Muhammad AseerDepartment of Physics, King Abdullah Campus, The University of Azad Jammu and Kashmir, Muzaffarabad, 13100, Pakistan.
Muhammad AtifDepartment of Physics and Astronomy, College of Science, King Saud University, Riyadh, 11451, Kingdom of Saudi Arabia.
Safdar AliDepartment of Cancer, Princess Margaret Cancer Centre, Toronto, Canada.

Funding

King Saud University, Riyadh, Saudi Arabia RSP2025R397
6 · The paper itself

Abstract

introductionIn this study, pure and cobalt manganese-doped ZnO nanoparticles (Zn

methodsThe hexagonal wurtzite structure of pure and co-doped ZnO NPs was confirmed by X-ray diffraction (XRD). The computed grain sizes of pure and co-doped ZnO NPs, according to Scherrer's formula, were 32 nm, 32.5 nm, 36.3 nm, and 36.5 nm, respectively. Scanning electron microscope (SEM) was used to observe the morphology of nanoparticles. FTIR spectroscopy was used to examine the chemical make-up and vibrational modes of pure and co-doped ZnO NPs. The bandgaps of pure and doped ZnO were examined using UV-Vis spectroscopy.

resultsIt was found that the optical bandgap of ZnO was lowered by 3.21 eV by manganese and cobalt doping. Elemental composition analysis was performed by using EDX analysis. Finally, anticancer activity of pure and co-doped ZnO NPs was assessed by employing MTT assay, which indicated that Zn

conclusionComprehensive experimental findings have demonstrated an authentic way of obtaining feasible in vivo liver cancer therapy.

Indexed as

Antineoplastic AgentsCobaltLiver NeoplasmsManganeseNanoparticlesZinc OxideCell ProliferationCell SurvivalDrug Screening Assays, AntitumorHep G2 CellsHumansParticle SizeAntineoplastic AgentsCobaltManganeseZinc OxidecobaltCo-doped ZnO NPsliver cancer therapyMTT assaypiezoelectric semiconductor.sol-gel method

Identifiers

PMID40103461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.